Toulouse (AFP)

The family of a 38-year-old woman, who died of thrombosis after receiving a first dose of the AstraZeneca vaccine, filed a complaint against X with the Toulouse prosecutor's office on Friday, with the aim of "obtaining an investigation", a his lawyer told AFP.

"It is a complaint against X, because we have no information against a named person, for manslaughter", underlined Me Étienne Boittin.

This qualification can "evolve according to the elements of the file", he specified.

The family of this social worker "is not in a process of claiming or seeking responsibilities, she simply wants explanations, clarifications on what happened," he added.

The thirty-something had been vaccinated in mid-March - as part of her professional activity in a medico-educational institute (IME) with disabled people - and did not suffer from any particular health problem, according to Me Boittin.

His state of health deteriorated shortly after his vaccination, requiring hospitalization at the Toulouse University Hospital.

She died on March 29 of a brain thrombosis.

"The objective of this complaint is to obtain additional investigations, in particular an autopsy in a medico-legal framework, with elements allowing us to know if this vaccine could have had a causal role in the occurrence of the death", affirmed the family lawyer.

He also defends the family of a Nantes medical student, who died suddenly at home of a thrombosis on March 18, a few days after an injection of the AstraZeneca vaccine.

In his case, the Nantes prosecutor's office opened a preliminary investigation.

The Medicines Agency (ANSM) confirmed on March 26 the existence of a "rare" risk of atypical thrombosis associated with AstraZeneca's Covid-19 vaccine, after the occurrence of new cases in France, while emphasizing that the risk / benefit balance remained "favorable".

The vaccine developed by the Swedish-British laboratory and the University of Oxford was suspended on March 15 by several European countries, after reports of cases of blood clots, sometimes fatal.

France lifted the suspension on March 19, after an opinion from the European Medicines Agency (EMA) deeming it "safe and effective".

© 2021 AFP